Demographic and clinical characteristics of patients with MDS after HMA failure receiving induction chemotherapy
| Variable . | Global . | 7+3 . | IDAC . | PNA . | P . |
|---|---|---|---|---|---|
| N | 307 | 173 | 44 | 90 | |
| Median age (range), y | 64 (22-85) | 65 (22-81) | 58 (24-85) | 66 (43-80) | <.01 |
| Sex, male/female (%) | 196/111 (64) | 116/57 (67) | 26/18 (59) | 54/36 (60) | .41 |
| t-MN, n (%) | 43 (14) | 23 (13) | 6 (14) | 14 (16) | .879 |
| Median WBC at induction (range), ×109/L | 2.6 (0.1-341) | 2.6 (0.1-341) | 3.3 (0.77-70) | 2.4 (1.1-14.7) | .829 |
| Cytogenetic risk, n (%) | |||||
| Favorable | 128 (42) | 69 (40) | 14 (32) | 45 (50) | .54 |
| Intermediate | 65 (21) | 36 (21) | 11 (25) | 18 (20) | |
| Unfavorable | 109 (36) | 65 (38) | 18 (41) | 26 (29) | |
| IPSS, n (%) | |||||
| Low | 8 (3.4) | 5 (4) | 0 (0) | 3 (4) | .191 |
| Int-1 | 67 (28) | 27 (22) | 11 (37) | 29 (35) | |
| Int-2 | 81 (34) | 42 (34) | 13 (43) | 26 (31) | |
| High | 80 (34) | 48 (40) | 6 (20) | 26 (31) | |
| Blast, % | 9.6 | 9.6 | 8.5 | 10.1 | .34 |
| Prior induction, n (%) | 7 (2) | 2 (1) | 4 (9) | 1 (1) | .42 |
| Prior allo-SCT, n (%) | 10 (3) | 2 (15) | 7 (16) | 1 (1) | <.01 |
| AZA/DEC (%) | 279/28 (91) | 156/17 (90) | 38/6 (86) | 85/5 (94) | .27 |
| Cycles of HMA, median (range) | 6 (1-72) | 6 (1-72) | 6 (1-38) | 6 (2-47) | .573 |
| Initiation of HMA to start of induction, median time (range), mo | 7.9 (0-72) | 8.4 (0-72) | 6.2 (0.6- 52.7) | 8.5 (1.8-51) | .23 |
| Variable . | Global . | 7+3 . | IDAC . | PNA . | P . |
|---|---|---|---|---|---|
| N | 307 | 173 | 44 | 90 | |
| Median age (range), y | 64 (22-85) | 65 (22-81) | 58 (24-85) | 66 (43-80) | <.01 |
| Sex, male/female (%) | 196/111 (64) | 116/57 (67) | 26/18 (59) | 54/36 (60) | .41 |
| t-MN, n (%) | 43 (14) | 23 (13) | 6 (14) | 14 (16) | .879 |
| Median WBC at induction (range), ×109/L | 2.6 (0.1-341) | 2.6 (0.1-341) | 3.3 (0.77-70) | 2.4 (1.1-14.7) | .829 |
| Cytogenetic risk, n (%) | |||||
| Favorable | 128 (42) | 69 (40) | 14 (32) | 45 (50) | .54 |
| Intermediate | 65 (21) | 36 (21) | 11 (25) | 18 (20) | |
| Unfavorable | 109 (36) | 65 (38) | 18 (41) | 26 (29) | |
| IPSS, n (%) | |||||
| Low | 8 (3.4) | 5 (4) | 0 (0) | 3 (4) | .191 |
| Int-1 | 67 (28) | 27 (22) | 11 (37) | 29 (35) | |
| Int-2 | 81 (34) | 42 (34) | 13 (43) | 26 (31) | |
| High | 80 (34) | 48 (40) | 6 (20) | 26 (31) | |
| Blast, % | 9.6 | 9.6 | 8.5 | 10.1 | .34 |
| Prior induction, n (%) | 7 (2) | 2 (1) | 4 (9) | 1 (1) | .42 |
| Prior allo-SCT, n (%) | 10 (3) | 2 (15) | 7 (16) | 1 (1) | <.01 |
| AZA/DEC (%) | 279/28 (91) | 156/17 (90) | 38/6 (86) | 85/5 (94) | .27 |
| Cycles of HMA, median (range) | 6 (1-72) | 6 (1-72) | 6 (1-38) | 6 (2-47) | .573 |
| Initiation of HMA to start of induction, median time (range), mo | 7.9 (0-72) | 8.4 (0-72) | 6.2 (0.6- 52.7) | 8.5 (1.8-51) | .23 |
AZA, azacitidine; DEC, decitabine; prior allo, prior allogeneic stem cell transplant; t-MN, therapy-related myeloid neoplasm.